Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio
Cogent Biosciences, Inc. (COGT)
Last cogent biosciences, inc. earnings: 11/8 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.cogint.com/investor-relations
Company Research
Source: GlobeNewswire
New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to be the first new therapy for second-line GIST in over 20 yearsClinical data presentations from all three pivotal trials, PEAK, SUMMIT and APEX, expected at major medical meetings in 1H 2026Investigational New Drug (IND) applications expected in 2026 for potentially best-in-class pan-KRAS(ON) and selective JAK2 V617F inhibitorsStrong financial position with ~$900 million cash to begin 2026, sufficient to fund commercial launches and operations well into 2028Company to present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 8:15 am PT/11:15 am ET WALTHAM, Mass. and BOULDER, Colo., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, t
Show less
Read more
Impact Snapshot
Event Time:
COGT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COGT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COGT alerts
High impacting Cogent Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
COGT
News
- Cogent Insider Sells $2.5 Million in Stock Amid Staggering 300% Price Surge [Yahoo! Finance]Yahoo! Finance
- H.C. Wainwright is Bullish on Cogent Biosciences, Inc. (COGT) [Yahoo! Finance]Yahoo! Finance
- Cogent Biosciences (NASDAQ:COGT) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.MarketBeat
- Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
COGT
Sec Filings
- 1/5/26 - Form 4
- 12/30/25 - Form 4
- 12/30/25 - Form 4
- COGT's page on the SEC website